Create profile
EN
CODEX News



Current Location: Home >> News>> Details

SARS-CoV-2 mutations amplify its advantage over host for efficient translation of viral RNAs

Source: Writer: Date:2021-09-17 View: 3544

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades host cells and, using cellular resources, rapidly proliferates. To control the coronavirus disease 2019 (COVID-19) pandemic and decipher the virus's molecular evolution, it is essential to understand how SARS-CoV-2 utilizes host cellular mechanisms to thrive. There have been many efforts to understand the molecular mechanisms of SARS-CoV-2 better. However, a definitive explanation of why this virus is so well adapted to invade human cells remains lacking.



A successful human cell invasion for SARS-CoV-2 is measured by how many viral particles are produced. Fast translation of viral RNAs is the basis of the rapid production of viral proteins, which requires further binding and scanning of ribosomes at the 5-prime end of mRNA, which allows for efficient translation initiation. Several approaches (cis and trans) are utilized by hosts that enhance the translation initiation efficiency, such as improving the initiation factors to elevate their efficiency or changing ribosomes to types with higher affinity to mRNAs.


A study published in the Journal of Applied Genetics shows that mutations that SARS-CoV-2 has gained improve its advantage in the efficient translation of viral RNAs. The authors explain that this strategy may assist the virus in adapting to human host cells.

The study

SARS-CoV-2 has 11 non-redundant coding sequences CDSs. The authors divided each CDS into ten bins with equal length and then calculated each bin's GC content. A significant difference was found in the SARS-CoV-2 5-prime bin, which had a low GC content compared to the other CDS. Human genes were found to have high GC content at the 5-prime end of CDS compared with the other parts. Due to only 11 genes being available with SARS-CoV-2, the was much more variance displayed. Opposite patterns between SARS-CoV-2 and humans were observed in the global trend.


Molecular basis of mRNA translation initiation. A No RNA structure near the start codon is favorable for efficient translation initiation. Strong RNA structure near the start codon usually leads to low initiation efficiency. B G:C base pair is biochemically more stable than A:U base pair. C Local RNA sequence with high GC content will lead to strong local structure, and vice versa


RNA structure stability is likely to increase with mutations resulting in higher GC content, such as A>G and T>C mutations. In contrast, an RNA structure could be unravelled or loosened by mutations that decrease GC content, such as G>A and C>T mutations.


The authors observed a decrease in RNA structure at the 5-prime CDS of SARS-CoV-2, so if this mechanism was advantageous to SARS-CoV-2, the virus sequence should continue to optimize. The mutation profile could reveal this long-lasting optimization process.


Fixed and polymorphic mutations are classifications that could be applied to these mutations. For example, within SARS-CoV-2, the fixed mutations are those diverged sites between RaTG13 and SARS-CoV-2, representing a relatively long timescale. Among the worldwide SARS-CoV-2 strains, the polymorphic mutations were detected in variant sites, which are now shaping natural selection events.


Between host cells and viruses, evolution is an ongoing arms race. Viral sequence "upgrading" does not guarantee successful viral invasion because optimization of host mRNA can also occur. SARS-CoV-2 mutations had a global trend to elevate the translation initiation efficiency of viral RNAs, while human mutations were "neutral" regarding host mRNA translation.

Conclusion

SARS-CoV-2 is, for the moment, ahead in the evolutionary arms race in terms of competing for ribosomes and rapid translation. However, this is not implying that novel mutations have any biases in SARS-CoV-2, as novel mutations are random. Still, viruses replicate faster than host cells, which allows for the accumulation of more mutations. Unfavorable mutations in viral sequences are eliminated by natural selection, leaving only the advantageous ones.


By Colin Lightfoot, M.Sc. Infection and Immunity Oct 19 2021 Reviewed by Danielle Ellis, B.Sc.

Hot News

SARS-CoV-2 mutations amplify its advantage over host for efficient translation of viral RNAs
Source: Writer: Date:2021-09-17 Views: 3544 次

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades host cells and, using cellular resources, rapidly proliferates. To control the coronavirus disease 2019 (COVID-19) pandemic and decipher the virus's molecular evolution, it is essential to understand how SARS-CoV-2 utilizes host cellular mechanisms to thrive. There have been many efforts to understand the molecular mechanisms of SARS-CoV-2 better. However, a definitive explanation of why this virus is so well adapted to invade human cells remains lacking.



A successful human cell invasion for SARS-CoV-2 is measured by how many viral particles are produced. Fast translation of viral RNAs is the basis of the rapid production of viral proteins, which requires further binding and scanning of ribosomes at the 5-prime end of mRNA, which allows for efficient translation initiation. Several approaches (cis and trans) are utilized by hosts that enhance the translation initiation efficiency, such as improving the initiation factors to elevate their efficiency or changing ribosomes to types with higher affinity to mRNAs.


A study published in the Journal of Applied Genetics shows that mutations that SARS-CoV-2 has gained improve its advantage in the efficient translation of viral RNAs. The authors explain that this strategy may assist the virus in adapting to human host cells.

The study

SARS-CoV-2 has 11 non-redundant coding sequences CDSs. The authors divided each CDS into ten bins with equal length and then calculated each bin's GC content. A significant difference was found in the SARS-CoV-2 5-prime bin, which had a low GC content compared to the other CDS. Human genes were found to have high GC content at the 5-prime end of CDS compared with the other parts. Due to only 11 genes being available with SARS-CoV-2, the was much more variance displayed. Opposite patterns between SARS-CoV-2 and humans were observed in the global trend.


Molecular basis of mRNA translation initiation. A No RNA structure near the start codon is favorable for efficient translation initiation. Strong RNA structure near the start codon usually leads to low initiation efficiency. B G:C base pair is biochemically more stable than A:U base pair. C Local RNA sequence with high GC content will lead to strong local structure, and vice versa


RNA structure stability is likely to increase with mutations resulting in higher GC content, such as A>G and T>C mutations. In contrast, an RNA structure could be unravelled or loosened by mutations that decrease GC content, such as G>A and C>T mutations.


The authors observed a decrease in RNA structure at the 5-prime CDS of SARS-CoV-2, so if this mechanism was advantageous to SARS-CoV-2, the virus sequence should continue to optimize. The mutation profile could reveal this long-lasting optimization process.


Fixed and polymorphic mutations are classifications that could be applied to these mutations. For example, within SARS-CoV-2, the fixed mutations are those diverged sites between RaTG13 and SARS-CoV-2, representing a relatively long timescale. Among the worldwide SARS-CoV-2 strains, the polymorphic mutations were detected in variant sites, which are now shaping natural selection events.


Between host cells and viruses, evolution is an ongoing arms race. Viral sequence "upgrading" does not guarantee successful viral invasion because optimization of host mRNA can also occur. SARS-CoV-2 mutations had a global trend to elevate the translation initiation efficiency of viral RNAs, while human mutations were "neutral" regarding host mRNA translation.

Conclusion

SARS-CoV-2 is, for the moment, ahead in the evolutionary arms race in terms of competing for ribosomes and rapid translation. However, this is not implying that novel mutations have any biases in SARS-CoV-2, as novel mutations are random. Still, viruses replicate faster than host cells, which allows for the accumulation of more mutations. Unfavorable mutations in viral sequences are eliminated by natural selection, leaving only the advantageous ones.


By Colin Lightfoot, M.Sc. Infection and Immunity Oct 19 2021 Reviewed by Danielle Ellis, B.Sc.

Our Advantages
Sixteen years of translation experience in medical and intellectual property fields
Sixteen years of translation experience in medical and intellectual property fields
Since the establishment, CODEX Translation has been deeply engaged in medical translation. Quality translation and services are the driving force for our sustainable development.
Professional and Elite Team
Professional and Elite Team
The translation team consists of graduates returned from abroad, post-graduate students from the most prestigious universities, professional native-speaking translators and consultants in the medical industry.
Authoritative Quality Certification
Authoritative Quality Certification
We provide services for many world-renowned pharmaceutical companies with ISO17100:2015,ISO18587:2017, ISO9001:2015, ISO14001:2015, ISO 13485:2016 Quality Management System Certification.
Strict Control Process
Strict Control Process
Codex Translation has established a perfect translation quality assurance system and systematic operation process, strictly adopts the working procedure of  “firstly translation, secondly modification, thirdly proofreading and fourthly review”.
Excellent Staff Quality
Excellent Staff Quality
Being strictly examined and selected, every one of us is characterized with a strong sense of responsibility and proficiency in medical translation , and we strictly follow the confidential system.
Client Support
Client Support
“Pursue Excellence, Strive for Perfection”. Serve you with quality and confidentiality .
Contact Us
CODEX By Your Side

Beijing CODEX Translation Co.,LTD

400-136-8786

We Are Here For You 24/7
Who We Are
As one of the few medical translation suppliers in China that have been certified by ISO17100: 2015, we have been providing life sciences translation services, localization services and intellectual property translation services since our founding 16 years ago.
Open a membership
Send a verification code
Sign up
Already have an account? Sign in here
Use your account
Use your message
Login
Do not have an account? Sign up here
Send a verification code
Login
Do not have an account? Sign up here
Scan QR code
CODEX WeChat Public Platform
WeChat
CODEX customer service
Contact Us
400-136-8786
E-mail
Info@codex-trans.com